Clinical trial
A Phase 1, Multicenter, Dose-Escalation Study to Investigate the Safety and Tolerability of ADH-1 in Combination With 1) Carboplatin or 2) Docetaxel or 3) Capecitabine in Subjects With N-Cadherin Positive, Advanced Solid Tumors (Adherex Protocol Number AHX-01-006)
NCT00390676 is registered in ClinicalTrials.gov with Adherex Technologies, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Multicenter, Dose-Escalation Study to Investigate the Safety and Tolerability of ADH-1 in Combination With 1) Carboplatin or 2) Docetaxel or 3) Capecitabine in Subjects With N-Cadherin Positive, Advanced Solid Tumors (Adherex Protocol Number AHX-01-006)
- Lead sponsor
- Adherex Technologies, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 30, 2006
- Completion date
- November 30, 2009
- Enrollment
- Not reported
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.